569 related articles for article (PubMed ID: 31182527)
1.
Pfaller MA; Huband MD; Flamm RK; Bien PA; Castanheira M
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182527
[TBL] [Abstract][Full Text] [Related]
2. Activities of Manogepix and Comparators against 1,435 Recent Fungal Isolates Collected during an International Surveillance Program (2020).
Pfaller MA; Huband MD; Rhomberg PR; Bien PA; Castanheira M
Antimicrob Agents Chemother; 2022 Nov; 66(11):e0102822. PubMed ID: 36286491
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018-2019).
Pfaller MA; Huband MD; Flamm RK; Bien PA; Castanheira M
J Glob Antimicrob Resist; 2021 Sep; 26():117-127. PubMed ID: 34051400
[TBL] [Abstract][Full Text] [Related]
4. Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods.
Castanheira M; Duncanson FP; Diekema DJ; Guarro J; Jones RN; Pfaller MA
Antimicrob Agents Chemother; 2012 Jan; 56(1):352-7. PubMed ID: 22083469
[TBL] [Abstract][Full Text] [Related]
5. Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018).
Pfaller MA; Carvalhaes C; Messer SA; Rhomberg PR; Castanheira M
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015043
[TBL] [Abstract][Full Text] [Related]
6. APX001A
Arendrup MC; Chowdhary A; Astvad KMT; Jørgensen KM
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30104264
[TBL] [Abstract][Full Text] [Related]
7. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.
Pfaller MA; Messer SA; Woosley LN; Jones RN; Castanheira M
J Clin Microbiol; 2013 Aug; 51(8):2571-81. PubMed ID: 23720791
[TBL] [Abstract][Full Text] [Related]
8. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds.
Miyazaki M; Horii T; Hata K; Watanabe NA; Nakamoto K; Tanaka K; Shirotori S; Murai N; Inoue S; Matsukura M; Abe S; Yoshimatsu K; Asada M
Antimicrob Agents Chemother; 2011 Oct; 55(10):4652-8. PubMed ID: 21825291
[TBL] [Abstract][Full Text] [Related]
10.
Pfaller M; Huband M; Bien PA; Carvalhaes CG; Klauer A; Castanheira M
Antimicrob Agents Chemother; 2024 Feb; 68(2):e0113223. PubMed ID: 38205999
[TBL] [Abstract][Full Text] [Related]
11. Manogepix (APX001A) Displays Potent
Arendrup MC; Jørgensen KM
Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32366708
[TBL] [Abstract][Full Text] [Related]
12.
Maphanga TG; Mpembe RS; Naicker SD; Govender NP;
Microbiol Spectr; 2022 Feb; 10(1):e0171721. PubMed ID: 35196811
[TBL] [Abstract][Full Text] [Related]
13.
Hager CL; Larkin EL; Long L; Zohra Abidi F; Shaw KJ; Ghannoum MA
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311065
[No Abstract] [Full Text] [Related]
14. Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012).
Pfaller MA; Messer SA; Jones RN; Castanheira M
J Antibiot (Tokyo); 2015 Sep; 68(9):556-61. PubMed ID: 25899126
[TBL] [Abstract][Full Text] [Related]
15.
Jørgensen KM; Astvad KMT; Arendrup MC
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513793
[TBL] [Abstract][Full Text] [Related]
16. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods.
Pfaller MA; Duncanson F; Messer SA; Moet GJ; Jones RN; Castanheira M
Antimicrob Agents Chemother; 2011 Nov; 55(11):5155-8. PubMed ID: 21844312
[TBL] [Abstract][Full Text] [Related]
18. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
19. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.
Guinea J; Peláez T; Recio S; Torres-Narbona M; Bouza E
Antimicrob Agents Chemother; 2008 Apr; 52(4):1396-400. PubMed ID: 18212101
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies.
Rivero-Menendez O; Cuenca-Estrella M; Alastruey-Izquierdo A
J Antimicrob Chemother; 2019 May; 74(5):1295-1299. PubMed ID: 30753499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
